Mostrar el registro sencillo del ítem
dc.contributor.author
Talevi, Alan
dc.contributor.author
Bellera, Carolina Leticia
dc.contributor.other
Talevi, Alan
dc.date.available
2021-12-17T11:53:41Z
dc.date.issued
2021
dc.identifier.citation
Talevi, Alan; Bellera, Carolina Leticia; Brain-to-Plasma Concentration Ratio and Unbound Partition Coefficient; Springer Nature Switzerland AG; 2021; 1-6
dc.identifier.isbn
978-3-030-51519-5
dc.identifier.uri
http://hdl.handle.net/11336/148932
dc.description.abstract
The brain-to-plasma concentration ratio (or totalbrain-to-plasma ratio, or simply, brain-to-plasma ratio, Kp, also referred toas B/P ratio or BB) is, as suggested by the name, the ratio between the total(bound and unbound) brain concentration Cbrain,ss and the total blood concentrationCblood.ss, at (pseudo)distribution equilibrium (steady state):Kp=Cbrain,ssCblood,ss(1) Kp has been extensively used atpreclinical drug development as an index of blood-brain barrier permeabilityand central nervous system (CNS) exposure. Alternatively to Eq. 1, it can alsobe computed as: Kp=AUCbrain,ssAUCblood,ss (2), where AUCbrain,ss denotes thearea under the curve of total concentrations in the brain (at steady state) andAUCblood,ss represents the area under the curve of total concentrations inblood (also at steady state). Often, Kp has been measured based on a crudehomogenization of brain tissue. Despite how tempting it may be to guidecompound optimization applying rapid in vitro assays, there is currentconsensus that the unbound brain-to-plasma ratio Kp,uu is much more relevant(or biorelevant) from a pharmacological perspective, as this parameter oftenshows a better correlation with receptor occupancy and other pharmacodynamicreadouts. This is because the magnitude of a pharmacological effect typicallydepends on the unbound (or free) drug levels in the biophase, and not on thetotal drug concentration. Since Kp is heavily influenced by nonspecificbinding, the efforts to optimize this parameter may in fact lead to anunproductive or even counterproductive design of drugs that have a high degreeof nonspecific (and pharmacodynamically inert) partitioning into brain tissue.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Springer Nature Switzerland AG
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
BRAIN BIOAVAILABILITY
dc.subject
CNS BIOAVAILABILITY
dc.subject
CENTRAL NERVOUS SYSTEM
dc.subject
DRUG BIOAVAILABILITY
dc.subject.classification
Otras Ciencias Biológicas
dc.subject.classification
Ciencias Biológicas
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS
dc.title
Brain-to-Plasma Concentration Ratio and Unbound Partition Coefficient
dc.type
info:eu-repo/semantics/publishedVersion
dc.type
info:eu-repo/semantics/bookPart
dc.type
info:ar-repo/semantics/parte de libro
dc.date.updated
2021-11-17T14:51:46Z
dc.journal.pagination
1-6
dc.journal.pais
Reino Unido
dc.journal.ciudad
Basignstoke
dc.description.fil
Fil: Talevi, Alan. Universidad Nacional de La Plata. Facultad de Ciencas Exactas. Laboratorio de Investigación y Desarrollo de Bioactivos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina
dc.description.fil
Fil: Bellera, Carolina Leticia. Universidad Nacional de La Plata. Facultad de Ciencas Exactas. Laboratorio de Investigación y Desarrollo de Bioactivos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://doi.org/10.1007/978-3-030-51519-5_61-1
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/referenceworkentry/10.1007%2F978-3-030-51519-5_61-1
dc.conicet.paginas
1500
dc.source.titulo
The ADME encyclopedia
Archivos asociados